CN106794169B - 无免疫抑制活性的维持神经再生活性的fk506衍生物及其用途 - Google Patents

无免疫抑制活性的维持神经再生活性的fk506衍生物及其用途 Download PDF

Info

Publication number
CN106794169B
CN106794169B CN201580041277.1A CN201580041277A CN106794169B CN 106794169 B CN106794169 B CN 106794169B CN 201580041277 A CN201580041277 A CN 201580041277A CN 106794169 B CN106794169 B CN 106794169B
Authority
CN
China
Prior art keywords
streptomyces
deoxy
prolyl
activity
demethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201580041277.1A
Other languages
English (en)
Chinese (zh)
Other versions
CN106794169A (zh
Inventor
尹汝准
权浩政
潘娟姬
S·普拉莫德布
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Morgen Biology Co ltd
Original Assignee
Intron Biotechnology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intron Biotechnology Inc filed Critical Intron Biotechnology Inc
Priority to CN201910404660.9A priority Critical patent/CN110251511A/zh
Publication of CN106794169A publication Critical patent/CN106794169A/zh
Application granted granted Critical
Publication of CN106794169B publication Critical patent/CN106794169B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
    • C12P17/16—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms containing two or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
    • C12P17/18—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms containing at least two hetero rings condensed among themselves or condensed with a common carbocyclic ring system, e.g. rifamycin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/465—Streptomyces

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
CN201580041277.1A 2014-08-01 2015-07-31 无免疫抑制活性的维持神经再生活性的fk506衍生物及其用途 Active CN106794169B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201910404660.9A CN110251511A (zh) 2014-08-01 2015-07-31 无免疫抑制活性的维持神经再生活性的fk506衍生物及其用途

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR10-2014-0099210 2014-08-01
KR1020140099210A KR101694879B1 (ko) 2014-08-01 2014-08-01 면역억제활성 없이 신경재생활성이 유지되는 fk506 유도체 및 그의 용도
PCT/KR2015/008031 WO2016018117A1 (ko) 2014-08-01 2015-07-31 면역억제활성 없이 신경재생활성이 유지되는 fk506 유도체 및 그의 용도

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201910404660.9A Division CN110251511A (zh) 2014-08-01 2015-07-31 无免疫抑制活性的维持神经再生活性的fk506衍生物及其用途

Publications (2)

Publication Number Publication Date
CN106794169A CN106794169A (zh) 2017-05-31
CN106794169B true CN106794169B (zh) 2020-02-04

Family

ID=55217893

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201580041277.1A Active CN106794169B (zh) 2014-08-01 2015-07-31 无免疫抑制活性的维持神经再生活性的fk506衍生物及其用途
CN201910404660.9A Pending CN110251511A (zh) 2014-08-01 2015-07-31 无免疫抑制活性的维持神经再生活性的fk506衍生物及其用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201910404660.9A Pending CN110251511A (zh) 2014-08-01 2015-07-31 无免疫抑制活性的维持神经再生活性的fk506衍生物及其用途

Country Status (6)

Country Link
US (2) US10226446B2 (https=)
EP (1) EP3187183B1 (https=)
JP (2) JP6370490B2 (https=)
KR (1) KR101694879B1 (https=)
CN (2) CN106794169B (https=)
WO (1) WO2016018117A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101694879B1 (ko) * 2014-08-01 2017-01-12 주식회사 인트론바이오테크놀로지 면역억제활성 없이 신경재생활성이 유지되는 fk506 유도체 및 그의 용도
US12011497B2 (en) * 2018-12-11 2024-06-18 Molgenbio Co. Ltd. Compounds, compositions containing same, and use thereof for promoting hair growth
US11449807B2 (en) 2020-01-31 2022-09-20 Walmart Apollo, Llc Systems and methods for bootstrapped machine learning algorithm training
JP7542876B2 (ja) * 2020-06-19 2024-09-02 モルジェンバイオ・カンパニー・リミテッド 神経突起成長及びシナプス形成活性を持つ新規プロリルｆｋ５０６誘導体及びその用途
CN118460433B (zh) * 2024-06-04 2026-01-06 浙江启臻合成生物技术有限公司 生产他克莫司的链霉菌工程菌及其构建方法与应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101573109A (zh) * 2006-12-28 2009-11-04 利默里克生物制药公司 用于治疗的方法和组合物
CN106572995A (zh) * 2014-06-30 2017-04-19 尹特荣生物科技株式会社 含有fk506衍生物的用于治疗隐球菌属霉菌和念珠菌属霉菌引起的真菌感染的药剂学组合物及其用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4894366A (en) * 1984-12-03 1990-01-16 Fujisawa Pharmaceutical Company, Ltd. Tricyclo compounds, a process for their production and a pharmaceutical composition containing the same
EP1595541A1 (en) * 2004-05-12 2005-11-16 Alcasynn Pharmaceuticals Gmbh Use of opioid receptor antagonist compounds for the prevention and/or treatment of diseases associated with the target calcineurin
WO2009158031A2 (en) * 2008-06-27 2009-12-30 Limerick Biopharma, Inc. Methods and compositions for therapeutic treatment
KR101261131B1 (ko) * 2010-08-24 2013-05-06 이화여자대학교 산학협력단 신규 타크롤리무스 유도체, 상기 유도체를 포함하는 신경 보호용 조성물, 상기 유도체를 포함하는 면역 억제용 조성물, 상기 유도체의 생산 방법 및 상기 유도체의 생산 균주
KR101694879B1 (ko) * 2014-08-01 2017-01-12 주식회사 인트론바이오테크놀로지 면역억제활성 없이 신경재생활성이 유지되는 fk506 유도체 및 그의 용도

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101573109A (zh) * 2006-12-28 2009-11-04 利默里克生物制药公司 用于治疗的方法和组合物
CN106572995A (zh) * 2014-06-30 2017-04-19 尹特荣生物科技株式会社 含有fk506衍生物的用于治疗隐球菌属霉菌和念珠菌属霉菌引起的真菌感染的药剂学组合物及其用途

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Characterization of FK506 biosynthetic intermediates involved in post-PKS elaboration;Yeon Hee Ban等;《J. Nat. Prod.》;20130524;第76卷(第6期);1091-1098 *

Also Published As

Publication number Publication date
EP3187183B1 (en) 2020-04-08
JP6370490B2 (ja) 2018-08-08
US10576060B2 (en) 2020-03-03
JP6851334B2 (ja) 2021-03-31
KR20160017267A (ko) 2016-02-16
JP2017523241A (ja) 2017-08-17
US20190134001A1 (en) 2019-05-09
EP3187183A1 (en) 2017-07-05
JP2018083843A (ja) 2018-05-31
EP3187183A4 (en) 2018-03-21
US20170216254A1 (en) 2017-08-03
KR101694879B1 (ko) 2017-01-12
WO2016018117A1 (ko) 2016-02-04
CN106794169A (zh) 2017-05-31
US10226446B2 (en) 2019-03-12
CN110251511A (zh) 2019-09-20

Similar Documents

Publication Publication Date Title
US10576060B2 (en) FK506 derivative maintaining nerve regeneration activity without immunosuppressive activity, and use thereof
KR101599982B1 (ko) 노노무라에아 종으로부터의 고리형 펩티드, 그에 대한 생산 프로세스 및 이를 포함하는 마이코박테리아 관련 질병의 치료 혹은 예방을 위한 약학적 조성물
Stierle et al. Caspase-1 and-3 inhibiting drimane sesquiterpenoids from the extremophilic fungus Penicillium solitum
CN103717222A (zh) 桥二硫二氧代哌嗪及其在治疗癌症方面的用途
Goudou et al. Orbicularisine: a spiro-indolothiazine isolated from gills of the tropical bivalve Codakia orbicularis
KR101261131B1 (ko) 신규 타크롤리무스 유도체, 상기 유도체를 포함하는 신경 보호용 조성물, 상기 유도체를 포함하는 면역 억제용 조성물, 상기 유도체의 생산 방법 및 상기 유도체의 생산 균주
Son et al. Polyketides and anthranilic acid possessing 6-deoxy-α-L-talopyranose from a Streptomyces Species
CN103857400A (zh) 玫瑰红景天提取物和分离的化合物及其在治疗神经变性疾病中的应用
Summers et al. 3-normeridamycin: a potent non-immunosuppressive immunophilin ligand is neuroprotective in dopaminergic neurons
JP2012184195A (ja) キシログラニンａ及びｂ
Kim et al. Discovery of 15-deoxynaphthomycins activating the antioxidant NRF2-ARE pathway from Streptomyces sp. N50 via genome mining, global regulator introduction, and molecular networking
KR20160067079A (ko) 면역억제활성 없이 신경재생활성이 유지되는 fk506 유도체 및 그의 용도
EP4169923B1 (en) Novel prolyl fk506 derivatives having neurite growth and synapse formation activities and uses thereof
EP3445741A1 (en) Antimicrobial agents
Bulusu et al. Chemistry of the immunomodulatory macrolide ascomycin and related analogues
US20090149395A1 (en) Novel macrocyclic polyene lactams
MX2013013863A (es) Antibioticos novedosos.
US20220009967A1 (en) Isolation and Semi-Synthesis of Rufomycin Analogs
KR20250165858A (ko) Staphylococcus xylosus로부터 분리한 신규 피라지논 유도체 및 이의 용도
Abdulkhair et al. Production and characterization of semi-quinolone antibiotic produced by Streptomyces griseorubens
KR20240099949A (ko) Pseudogymnoascus sp. SF-7351 유래 마크로스펠라이드의 신규한 용도
CN103374057B (zh) 一种对甘氨酸转运子具有抑制活性的化合物
WO2015145152A1 (en) Antimicrobial agents
JP5718450B2 (ja) 抗悪性腫瘍剤およびその製造方法と用途
CN117769601A (zh) 化合物、其制造方法、抗菌剂和医药品

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
TR01 Transfer of patent right

Effective date of registration: 20240115

Address after: Seoul special city

Patentee after: Morgen biology Co.,Ltd.

Address before: Gyeonggi Do, South Korea

Patentee before: INTRON BIOTECHNOLOGY, Inc.

TR01 Transfer of patent right